pentoxyphylline
Phase 3Small molecule
pentoxyphylline is one of 41 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Truphylline
TThe Searle Company Limited Pakistan
Phase 3
Arginine Vasopressin
SStanford University
Phase 3
NORADRENALIN
UUniversity of Aarhus
Phase 3
Crestor
AstraZenecaPreclinical
pentoxyphylline
NNational Taiwan University Hospital
Phase 3
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Proamatine
TakedaPreclinical
Lexapro
AbbViePreclinical
Lescol
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pentoxyphylline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details